Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est
Jazz Pharmaceuticals (NASDAQ: JAZZ ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion vs $4.517 billion estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.